Stockreport

Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Sagimet Biosciences Inc.  (SGMT) 
PDF Denifanstat received Breakthrough Therapy designation from FDA for MASH Results from Phase 2b FASCINATE-2 study of denifanstat published in The Lancet Gastroenterology [Read more]